All In Biotech

Drug Trial Radar · NCT06003751

A Study of PER-001 in Participants With Diabetic Retinopathy

A Phase 2a Study to Evaluate Safety and Tolerability After Single Administration of PER-001 Intravitreal Implant in Participants With Diabetic Retinopathy

Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Aug 5, 2023

Primary completion

Apr 3, 2025

Study completion Dec 10, 2025

Sponsor

Lead sponsor
Perfuse Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 2a, randomized, single-masked (participant), sham controlled clinical study.

Conditions

  • Diabetic Retinopathy

Interventions

  • PER-001 Intravitreal Implant - Low DoseDrug

    PER-001 Low Dose Intravitreal Implant

  • PER-001 Intravitreal Implant - High DoseDrug

    PER-001 High Dose Intravitreal Implant

  • PER-001 Intravitreal Implant - ShamDrug

    PER-001 Intravitreal Sham

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best-corrected Visual Acuity (BCVA)Time frame: End of Study(Week 24)
  2. Intraocular Pressure (IOP)Time frame: End of Study(Week 24)
  3. Ocular Adverse eventsTime frame: End of Study(Week 24)
  4. Systemic Adverse eventsTime frame: End of Study(Week 24)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Perfuse Therapeutics, Inc

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.